Drug safety sciences and the bottleneck in drug development

During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical pharmacology and therapeutics Vol. 89; no. 6; p. 788
Main Author:	Watkins, P B
Format:	Journal Article
Language:	English
Published:	United States 01.06.2011
Subjects:	Animals Clinical Trials as Topic - economics Clinical Trials as Topic - methods Drug Approval - economics Drug Approval - methods Drug Discovery - economics Drug Discovery - methods Drug Discovery - standards Drug-Related Side Effects and Adverse Reactions - economics Drug-Related Side Effects and Adverse Reactions - prevention & control Humans United States United States
ISSN:	1532-6535, 1532-6535
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	During a recent review of a new drug application for treatment of a chronic disease, US Food and Drug Administration (FDA) regulators agreed with the sponsor's assessment of efficacy. However, it was noted that two subjects receiving active treatment experienced abnormal liver chemistries that possibly, but not definitely, indicated a liver safety liability. The sponsor was told that a prerequisite for approval would be a new clinical trial involving 20,000 patients treated for 1 year, with 10,000 receiving the new drug and 10,000 receiving a comparator treatment. The sponsor is now faced with the substantial costs involved in undertaking such a large study, the loss of patent life during the conduct and analysis of the study, and the prospect of losing in-class market position. If the drug is ultimately approved, this detour will result in costs and potential revenue loss to the sponsor of well over $1 billion.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1532-6535 1532-6535
DOI:	10.1038/clpt.2011.63